Indicated as now closed down, Daktari Diagnostics, Inc. had been a biotechnology and medical device company focused to medical diagnostic equipment enabling enhanced disease management in both developed and developing countries. The firm's portable point-of-care diagnostic platform, with built-in wireless connectivity and an intuitive cloudbased data management system, provides the real-time information necessary to improve clinical outcomes for individual patients and support global disease elimination programs. Daktaris initial products will target viruses of worldwide significance, including Hepatitis C and HIV. The company recently announced a Hepatitis C partnership with Merck & Co (MSD). Daktari has three main products in development. First. CD4 system, a portable and robust blood test-based diagnostic system that utilizes Daktari's proprietary technologies in microfluidics and electrochemical sensing. The system is battery powered and utilizes a single use microfluidic assay cartridge. Particularly targeted at HIV treatment, the devices is able to deliver an accurate white-blood cell count. Second, Daktari is developing a data management system that enables its devices to securely communicate with medical systems and databases. Finally, early-stage development has begun on a device to measure viral load in patients. Some of the technologies underpinning Daktari's products were licensed from Massachusetts General Hospital
